Also trades as: UNH.NE (NEO) · $vol 3M · UNH.TO (TSX) · $vol 1M · UNH.DE (XETRA) · $vol 0M · UNH.BA (BUE) · $vol 0M
UNH NYSE
UnitedHealth Group Incorporated
1W: -2.1%
1M: +8.6%
3M: -2.4%
YTD: +22.0%
1Y: +14.0%
3Y: -18.7%
5Y: +3.8%
$410.39
-0.31 (-0.08%)
Weekly Expected Move ±4.1%
$384
$401
$418
$435
$452
Credit Risk of going bust: lower than 67% of companies Debt: 16.8% of company value Bonds: $1.52B held by 566 funds, 74 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $6.63 (down 98%), UnitedHealth Group Incorporated would be worth roughly what it owes.
Total debt $74.33B against a stock market value of $368.36B.
Distance to default 7.08 (Merton model): prices to 2026-10-27, balance sheet 2026-09-30, debt counted $39.97B (short-term plus half of long-term), stock volatility 36.0%; Altman Z'' 0.40. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $6.63 (down 98%), UnitedHealth Group Incorporated would be worth roughly what it owes.
Total debt $74.33B against a stock market value of $368.36B.
Distance to default 7.08 (Merton model): prices to 2026-10-27, balance sheet 2026-09-30, debt counted $39.97B (short-term plus half of long-term), stock volatility 36.0%; Altman Z'' 0.40. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#1
of 19
Medical - Healthcare Plans
Technical Signal Map
10 Bullish
0 Neutral
1 Bearish
UNH
$375B
UnitedHealth Group Incorporated
BULLISH
+41
ABBV
$505B
AbbVie Inc.
BULLISH
+100
JNJ
$636B
Johnson & Johnson
BULLISH
+91
TMO
$249B
Thermo Fisher Scientific Inc.
BULLISH
+91
RHHBF
$393B
Roche Holding AG
BULLISH
+75
NVS
$287B
Novartis AG
BULLISH
+75
LLY
$1.2T
Eli Lilly and Company
BULLISH
+66
AMGN
$237B
Amgen Inc.
BULLISH
+66
SRTOY
$228B
Sartorius Stedim Biotech S.A.
BULLISH
+50
AZN
$266B
AstraZeneca PLC
LEAN BULL
+25
MRK
$358B
Merck & Co., Inc.
BEARISH
-68
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
| UNH UnitedHealth Group Incorporated | $375B | 23.4 | 15.9 | 13.5 | 3.6 | 3.3 | 7 | BULLISH | 14.0 |
| ABBV AbbVie Inc. | $505B | 80.7 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 25.6 |
| JNJ Johnson & Johnson | $636B | 40.7 | 20.0 | 21.3 | 0.8 | 7.8 | 6 | BULLISH | 42.0 |
| TMO Thermo Fisher Scientific Inc. | $249B | 36.5 | 13.4 | 8.6 | 14.2 | 8.3 | 8 | BULLISH | 21.2 |
| RHHBF Roche Holding AG | $393B | 26.0 | 40.2 | 24.6 | 22.6 | 27.8 | 6 | BULLISH | 30.5 |
| NVS Novartis AG | $287B | 23.6 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BULLISH | 20.3 |
| LLY Eli Lilly and Company | $1.2T | 42.9 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | BULLISH | 55.5 |
| AMGN Amgen Inc. | $237B | 27.6 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 57.8 |
| SRTOY Sartorius Stedim Biotech S.A. | $228B | 66.4 | 7.4 | 6.2 | 12.5 | 4.4 | 8 | BULLISH | -0.5 |
| AZN AstraZeneca PLC | $266B | 25.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | LEAN BULL | 4.5 |
| MRK Merck & Co., Inc. | $358B | 112.6 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | BEARISH | 63.5 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
UNH vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F